IRIS UniCatt

Fabbiani, Massimiliano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.318
NA - Nord America 4.532
AS - Asia 2.758
SA - Sud America 480
AF - Africa 78
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 5
AN - Antartide 1
Totale 13.179
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.408
IT - Italia 1.412
SG - Singapore 1.265
DE - Germania 1.258
CN - Cina 719
SE - Svezia 595
FR - Francia 562
PL - Polonia 451
BR - Brasile 380
UA - Ucraina 332
VN - Vietnam 205
GB - Regno Unito 201
IE - Irlanda 141
IN - India 140
FI - Finlandia 90
ID - Indonesia 86
NL - Olanda 82
RU - Federazione Russa 68
TR - Turchia 68
CA - Canada 60
HK - Hong Kong 47
JP - Giappone 46
AR - Argentina 44
BD - Bangladesh 40
MX - Messico 34
BE - Belgio 26
ZA - Sudafrica 25
IQ - Iraq 22
IR - Iran 19
ES - Italia 17
VE - Venezuela 15
AT - Austria 11
EC - Ecuador 11
EG - Egitto 11
PH - Filippine 11
PK - Pakistan 11
JM - Giamaica 10
LT - Lituania 10
MA - Marocco 9
SA - Arabia Saudita 9
CH - Svizzera 8
KE - Kenya 8
UZ - Uzbekistan 8
AZ - Azerbaigian 7
CZ - Repubblica Ceca 7
PE - Perù 7
PY - Paraguay 7
TN - Tunisia 7
EU - Europa 6
IL - Israele 6
KZ - Kazakistan 6
DK - Danimarca 5
JO - Giordania 5
KR - Corea 5
PS - Palestinian Territory 5
AL - Albania 4
BO - Bolivia 4
CL - Cile 4
CO - Colombia 4
DZ - Algeria 4
ET - Etiopia 4
HN - Honduras 4
LB - Libano 4
PA - Panama 4
PT - Portogallo 4
RO - Romania 4
BG - Bulgaria 3
DO - Repubblica Dominicana 3
GR - Grecia 3
LU - Lussemburgo 3
MY - Malesia 3
NI - Nicaragua 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
BH - Bahrain 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
HR - Croazia 2
HU - Ungheria 2
IM - Isola di Man 2
KG - Kirghizistan 2
LK - Sri Lanka 2
MC - Monaco 2
NG - Nigeria 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
OM - Oman 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
AG - Antigua e Barbuda 1
AM - Armenia 1
AO - Angola 1
AQ - Antartide 1
BB - Barbados 1
BN - Brunei Darussalam 1
BS - Bahamas 1
CD - Congo 1
CR - Costa Rica 1
CY - Cipro 1
Totale 13.157
Salva come PNG Salva come JPEG
Città #
Chandler 653
Singapore 631
Ashburn 512
Kraków 426
San Jose 336
Rome 328
Jacksonville 248
New York 186
Milan 185
San Mateo 156
Dublin 139
Nanjing 135
Ann Arbor 122
Beijing 102
Los Angeles 99
Dearborn 86
Lauterbourg 84
Nürnberg 83
Houston 82
Jakarta 82
Wilmington 77
Ho Chi Minh City 74
The Dalles 72
Lawrence 71
Cattolica 66
Woodbridge 62
Boston 59
Nanchang 57
Lancaster 53
Dallas 51
Redmond 50
Hanoi 49
Izmir 46
Redwood City 42
Hong Kong 41
Seattle 38
Tokyo 37
Frankfurt am Main 35
Hefei 34
Shenyang 34
Verona 32
Moscow 31
Boardman 30
Buffalo 28
Munich 28
São Paulo 27
Brussels 26
Bremen 25
Kunming 25
Naples 25
Santa Clara 24
Turin 24
Changsha 23
Fairfield 23
Mountain View 23
Hebei 22
Norwalk 21
Orem 21
Falls Church 20
Warsaw 20
Shanghai 19
Düsseldorf 18
Montreal 18
Ottawa 18
Leawood 17
University Park 17
Bologna 16
Augusta 15
Brooklyn 15
Johannesburg 15
Marseille 15
Tianjin 15
Toronto 15
Chicago 14
Guangzhou 14
London 14
Chennai 13
Hangzhou 13
Jinan 13
Paris 13
Poplar 13
Rio de Janeiro 13
Fremont 12
Manchester 12
Pune 12
Atlanta 11
Bari 11
Phoenix 11
Roubaix 11
Washington 11
Brasília 10
Brescia 10
Catania 9
Da Nang 9
Haiphong 9
Helsinki 9
Palermo 9
Simi Valley 9
Stockholm 9
Amsterdam 8
Totale 6.736
Salva come PNG Salva come JPEG
Nome #
IL PRIVATO SOCIALE: UN'OPPORTUNITÀ PER I PAZIENTI E PER LE STRUTTURE SANITARIE NELL'ATTUALE CONTESTO ECONOMICO 1.385
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 269
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 253
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 226
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 218
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 218
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 217
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 210
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 203
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 199
Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance 194
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 189
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 186
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 186
Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure 186
Verbal list learning and memory profiles in HIV-infected adults, Alzheimer's disease, and Parkinson's disease: An evaluation of the "cortical hypothesis" of NeuroAIDS 184
Clinical presentation, microbiological features and correlates of disease severity of 2009 pandemic influenza A (H1N1) infection 182
Variability of raltegravir plasma levels in the clinical setting 181
Prospective evaluation of epidemiological, clinical, and microbiological features of pandemic influenza A (H1N1) virus infection in Italy 176
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy 176
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 176
Initial antifungal strategy does not correlate with mortality in patients with candidemia 174
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. 169
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 168
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction 167
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 166
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 165
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 165
Validation of an UPLC-MS/MS Method for Quantitative Analysis of Raltegravir in Human Plasma Samples 162
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 162
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 158
Cognitive reserve and neuropsychological functioning in older HIV-infected people 156
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 155
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 154
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 154
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort) 153
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy 152
Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: two years experience in routine clinical practice 150
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 149
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study 149
Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. 148
Cardiovascular risk factors and carotid intima-media thickness are associated with low cognitive performance in HIV-infected patients 148
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 147
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 147
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1 147
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. 145
Effect of aging and human immunodeficiency virus infection on cognitive abilities 144
Immune response to influenza A(H1N1)v in HIV-infected patients 144
HIV-infected patients show impaired cellular immune response to influenza vaccination, compared to healthy subjects 142
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 142
Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients 141
Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients 139
Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data 138
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 137
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 137
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: A multicenter observational study 136
Resource-saving advice from an infectious diseases specialist team in a large university hospital: an exportable model? 135
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial 135
Exploratory analysis for the evaluation of estimated glomerular filtration rate, cholesterol and triglycerides after switching from tenofovir/emtricitabine plus atazanavir/ritonavir (ATV/r) to abacavir/lamivudine plus ATV/r in patients with preserved renal function 134
HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects 133
Liver fibrosis progression and clinical outcomes are intertwined: Role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCVcoinfected patients with detectable HCV-RNA A MASTER cohort study 133
Coccidioidomycosis of cervical lymph nodes in an HIV-infected patient with immunologic reconstitution on potent HAART: a rare observation in a nonendemic area 132
The threshold bootstrap clustering: a new approach to find families or transmission clusters within molecular quasispecies 130
Lipid-lowering effect of tenofovir in HIV-infected patients 127
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients 125
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. 121
Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine 120
Immune response to influenza A(H1N1)v in HIV-infected patients 119
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis 117
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 116
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir 109
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 103
Switching to Coformulated Rilpivirine/Emtricitabine/Tenofovir in Virologically Suppressed Patients: Data From a Multicenter Cohort 95
Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART 87
Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009 86
Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors 83
Is there a drug-drug interaction between darunavir/ritonavir and raltegravir? 79
Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received 78
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 78
Totale 13.299
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.329
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.329
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021159 0 0 0 0 0 0 0 0 0 22 121 16
2021/2022806 77 64 25 61 47 40 21 129 29 73 121 119
2022/20231.639 237 261 132 258 136 191 29 145 186 11 39 14
2023/20241.021 41 231 30 106 45 212 68 22 30 50 116 70
2024/20251.913 55 55 120 103 222 89 99 160 332 154 294 230
2025/20263.632 570 97 200 442 721 201 647 227 252 275 0 0
Totale 13.299